
“With this product and our solar keratosis product Picato, which we launched on the US market earlier this year, we find ourselves in a situation where a new market has opened up, which is actually bigger than our total market so far,” says Jacob Anker Rasmussen, VP of Global Sales and Marketing in Leo Pharma.
His words stress the importance of FDA’s recent approval of Leo Pharma’s gel product, Taclonex, for a new indication within psoriasis.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app